Page 51 - Felix Nipkow News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Felix nipkow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Felix Nipkow Today - Breaking & Trending Today

Scientists discover hidden intricacies of sperm motility

Researchers at Stockholm University have unveiled the hidden intricacies of how sperm go from passive bystanders to dynamic swimmers. ....

Megan Craig , David Drew , Stockholm University , European Research Council , Researchers At Stockholm University ,

Lithium X Energy (CVE:LIX) Stock Price Crosses Below Fifty Day Moving Average of $2.57

Shares of Lithium X Energy Corp. (CVE:LIX – Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$2.57 and traded as low as C$2.54. Lithium X Energy shares last traded at C$2.57, with a volume of 1,695,499 shares traded. Lithium […] ....

United States , Los Angeles , Lithiumx Energy Trading , Lithiumx Energy Corp , News Ratings For Lithiumx Energy Daily , Lithiumx Energy , Royce Resources Corp , Get Free Report , Sal De Los Angeles , Salta Province , Royce Resources , Lithiumx Energy Daily , Cve Lix ,

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

The study has achieved its primary objectives, confirming the safety and tolerability profile of TLX591 administered in two doses, two weeks apart in combination with standard of care (SoC) Preliminary activity demonstrates meaningfulPSA[1] reduction; monitoring of patients is ongoing, including for rPFS[2] Findings reinforce the potential advantages of this first-in-class radio-antibody drug conjugate (rADC) investigational therapy, consistent with previous clinical studies of TLX591[3] MELBOURNE, Australia, Oct. 19, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces positive preliminary results from the Phase I ProstACT SELECT study of its rADC therapy candidate TLX591 (Lutetium (177Lu) rosopatamab tetraxetan) for prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC). The purpose of the SELECT study (ClinicalTrials.gov ID: NCT04786847)was to evaluate the utility of PSMA imaging to select ....

New York , United States , United Kingdom , Scottt Tagawa , Nat Lenzo , Colin Hayward , Kyahn Williamson , Corporate Communications , Telix Pharmaceuticals Limited Disclosure Committee , Drug Administration , Prnewswire Telix Pharmaceuticals Limited , European Union , Telix Pharmaceuticals , Australian Therapeutic Goods Administration , Genesiscare Group Clinical , Australian Securities Exchange , Health Canada , Pharmaceuticals Limited , Genesiscare Group Clinical Director Theranostics , Telix Chief Medical Officer , Marketing Authorisation Applications , Telix Pharmaceuticals Limited , The Study Has Achieved Its Primary Objectives , Onfirming The Safety And Tolerability Profile Of Tlx591 Administered In Two Doses , Wo Weeks Apart In Combination With Standard Of Care Soc Preliminary Activity Demonstrates Meaningfulpsa 1 Reduction Monitoring Patients Is Ongoing , Ncluding For Rpfs 2 Findings Reinforce The Potential Advantages Of This First In Class Radio Antibody Drug Conjugate Radc Investigational Therapy ,